Adenoviral CD40 Ligand Immunotherapy in 32 Canine Malignant Melanomas-Long-Term Follow Up

Show full item record



Permalink

http://hdl.handle.net/10138/334631

Citation

Saellstrom , S , Sadeghi , A , Eriksson , E , Segall , T , Dimopoulou , M , Korsgren , O , Loskog , A SI , Totterman , T H , Hemminki , A & Ronnberg , H 2021 , ' Adenoviral CD40 Ligand Immunotherapy in 32 Canine Malignant Melanomas-Long-Term Follow Up ' , Frontiers in Veterinary Science , vol. 8 , 695222 . https://doi.org/10.3389/fvets.2021.695222

Title: Adenoviral CD40 Ligand Immunotherapy in 32 Canine Malignant Melanomas-Long-Term Follow Up
Author: Saellstrom, Sara; Sadeghi, Arian; Eriksson, Emma; Segall, Thomas; Dimopoulou, Maria; Korsgren, Olle; Loskog, Angelica SI.; Totterman, Thomas H.; Hemminki, Akseli; Ronnberg, Henrik
Other contributor: University of Helsinki, Department of Oncology



Date: 2021-07-23
Language: eng
Number of pages: 12
Belongs to series: Frontiers in Veterinary Science
ISSN: 2297-1769
DOI: https://doi.org/10.3389/fvets.2021.695222
URI: http://hdl.handle.net/10138/334631
Abstract: Malignant melanoma is a serious disease in both humans and dogs, and the high metastatic potential results in poor prognosis for many patients. Its similarities with human melanoma make spontaneous canine melanoma an excellent model for comparative studies of novel therapies and tumor biology. Gene therapy using adenoviruses encoding the immunostimulatory gene CD40L (AdCD40L) has shown promise in initial clinical trials enrolling human patients with various malignancies including melanoma. We report a study of local AdCD40L treatment in 32 cases of canine melanoma (23 oral, 5 cutaneous, 3 ungual and 1 conjunctival). Eight patients were World Health Organization (WHO) stage I, 9 were stage II, 12 stage III, and 3 stage IV. One to six intratumoral injections of AdCD40L were given every seven days, combined with cytoreductive surgery in 20 cases and only immunotherapy in 12 cases. Tumor tissue was infiltrated with T and B lymphocytes after treatment, suggesting immune stimulation. The best overall response based on result of immunotherapy included 7 complete responses, 5 partial responses, 5 stable and 2 progressive disease statuses according to the World Health Organization response criteria. Median survival was 285 days (range 20-3435 d). Our results suggest that local AdCD40L therapy is safe and could have beneficial effects in dogs, supporting further treatment development. Clinical translation to human patients is ongoing.
Subject: immuno oncology
adenoviral vectors
translational medicine
canine malignant melanoma
clinical trials
AdCD40L
LOW-DOSE CYCLOPHOSPHAMIDE
ADCD40L GENE-THERAPY
SURGICAL EXCISION
DENDRITIC CELLS
CANCER BIOLOGY
DOGS
TUMORS
SURVIVAL
BEHAVIOR
VACCINE
413 Veterinary science
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
fvets_08_695222.pdf 1.133Mb PDF View/Open

This item appears in the following Collection(s)

Show full item record